Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBShield: diacerein 1% ointment for generalized epidermolysis bullosa simplex
CTR20260850Phase 3Active
- Sponsor
- Ancheng Biotech
- Start
- Apr 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of diacerein in epidermolysis bullosa simplex (EBS), sponsored by Ancheng Biotech. Started Apr 2024; status: active.
02
Drugs
diacerein
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on CTR20260850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260850.